Bionano (BNGO) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $8.2 million, up 21% year-over-year, exceeding guidance of $7.5 million to $7.8 million.

Flow Cell Sales: 9.22 thousand units sold, a 27% increase year-over-year, marking a record quarter.

Consumable Revenue: $4.3 million, up 30% year-over-year.

Software Revenue: $1.4 million, down 16% year-over-year due to deployment delays.

Other Revenue: $2.5 million, up 38% year-over-year, driven by higher instrument sales.

Gross Margin: Adjusted gross margin reached 53%, an increase from 52% in Q2 2025.

Operating Expenses: $8.7 million, slightly down from $8.8 million in Q2 2025.

Cash Position: $10.4 million in cash and equivalents, with a cash runway extending into Q1 2027.

2Strategic Updates and Business Highlights

Leadership Change: Dr. Alex Hastie returns as Chief Scientific Officer, reinforcing the company's commitment to scientific leadership.

Focus on Routine Users: The strategy has shifted towards profitable growth with existing customers rather than aggressive expansion.

Growth Drivers: Increased clinical adoption of Optical Genome Mapping (OGM) is a key factor, with a significant rise in flow cell utilization among existing users.

International Growth: International revenue now constitutes the majority of total revenue, driven by clinical adoption in Europe.

Reimbursement Progress: New CPT codes for OGM are expected to enhance adoption in hematology and genetic disorders.

3Forward Guidance and Outlook

2026 Revenue Guidance: Raised to $31 million to $33 million, reflecting 9% to 16% growth over 2025.

Q3 2026 Guidance: Expected revenue of $8.2 million to $8.6 million, indicating 11% to 16% growth year-over-year.

Profitability Goal: The company aims for adjusted EBITDA breakeven as it continues to improve margins and reduce operating costs.

4Bad News, Challenges, or Points of Concern

Manufacturing Constraints: The company is facing supply constraints that limit its ability to meet demand, impacting revenue potential.

Cautious Guidance: The upper end of revenue guidance was not raised due to uncertainty in manufacturing capacity.

Software Revenue Decline: A notable decrease in software revenue highlights potential challenges in deployment and customer adoption.

5Notable Q&A Insights

Growth Sources: The majority of growth is attributed to increased utilization by existing clients rather than new customer acquisitions.

CPT Code Impact: Initial signs suggest that new CPT codes are beginning to drive sales, but full effects are still uncertain.

Revenue Recognition: The difference between consumables sold and revenue growth is partly due to customers on reagent rental agreements, leading to deferred revenue recognition. Overall, Bionano reported strong financial results driven by increased adoption of its products, despite facing challenges related to manufacturing capacity and software revenue declines. The company remains focused on enhancing profitability and expanding its market presence.